We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Danakali Limited | LSE:DNK | London | Ordinary Share | AU000000DNK9 | ORDS NPV |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 20.00 | 19.00 | 21.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMDNK
RNS Number : 4626V
Danakali Limited
03 December 2019
Rule 2.7, 3.10.3, 3.10.4, 3.10.5
Appendix 3B
New issue announcement,
application for quotation of additional securities
and agreement
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.
Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13
Name of entity DANAKALI LTD ABN 56 097 904 302
We (the entity) give ASX the following information.
Part 1 -- All issues
You must complete the relevant sections (attach sheets if there is not enough space).
Hot Features
Premium
1 +Class of +securities Ordinary shares
issued or to be issued
2 Number of +securities 123,001,231 shares
issued or to be issued in total have been
(if known) or maximum agreed to be issued
number which may be pursuant to the
issued Placement
announced 3 December
2019.
The issue of
Placement
shares will be
undertaken
in two tranches, as
follows:
(a) Tranche 1 -
52,958,908
shares
(b) Tranche 2 -
70,042,323
shares (subject to
receipt of
shareholder
approval and
conditions
as set out in the
ASX
Announcement dated
3 December 2019)
3 Principal terms of Fully paid ordinary
the +securities (e.g. shares
if options, exercise
price and expiry date;
if partly paid +securities,
the amount outstanding
and due dates for
payment; if +convertible
securities, the conversion
price and dates for
conversion)
4 Do the +securities Yes - fully paid ordinary
rank equally in all shares
respects from the
+issue date with an
existing +class of
quoted +securities?
If the additional
+securities do not
rank equally, please
state:
* the date from which they do
* the extent to which they participate for the next
dividend, (in the case of a trust, distribution) or
interest payment
* the extent to which they do not rank equally, other
than in relation to the next dividend, distribution
or interest payment
5 Issue price or consideration $0.60 per share
6 Purpose of the issue The majority of proceeds from
(If issued as consideration AFC's equity investment will
for the acquisition be used to commence project
of assets, clearly execution for the Colluli Sulphate
identify those assets) of Potash Project. A portion
of the proceeds will be used
to cover the costs of the associated
transaction and to top up Danakali's
working capital.
6a Is the entity an +eligible Yes
entity that has obtained
security holder approval
under rule 7.1A?
If Yes, complete sections
6b - 6h in relation
to the +securities
the subject of this
Appendix 3B, and comply
with section 6i
6b The date the security 27 May 2019
holder resolution
under rule 7.1A was
passed
6c Number of +securities (a) 26,364,563 of the Tranche
issued without security 1 shares
holder approval under
rule 7.1
6d Number of +securities (a) 26,594,345 of the Tranche
issued with security 1 shares
holder approval under
rule 7.1A
6e Number of +securities (b) 70,042,323 Tranche 2 shares
issued with security (subject to receipt of shareholder
holder approval under approval and conditions as set
rule 7.3, or another out in the ASX Announcement
specific security dated 3 December 2019)
holder approval (specify
date of meeting)
6f Number of +securities N/A
issued under an exception
in rule 7.2
6g If +securities issued Yes. The $0.60 issue price is
under rule 7.1A, was 94% of the Company's 15-day
issue price at least VWAP as of the date the shares
75% of 15 day VWAP were agreed to be issued (3
as calculated under December 2019) of $0.6378 (Listing
rule 7.1A.3? Include Rule 7.1A.3(a)).
the +issue date and
both values. Include VWAP source data: Yahoo Finance
the source of the
VWAP calculation.
6h If +securities were N/A
issued under rule
7.1A for non-cash
consideration, state
date on which valuation
of consideration was
released to ASX Market
Announcements
6i Calculate the entity's Capacity under L.R.7.1 - 8,763,882
remaining issue capacity Capacity under LR7.1A - Nil
under rule 7.1 and
rule 7.1A - complete
Annexure 1 and release
to ASX Market Announcements
7 +Issue dates (a) Tranche 1 shares are anticipated
Note: The issue date to be issued on or about 9 December
may be prescribed 2019
by ASX (refer to the (b) Tranche 2 shares are anticipated
definition of issue to be issued early March 2020
date in rule 19.12). (subject to receipt of shareholder
For example, the issue approval and conditions as set
date for a pro rata out in the ASX Announcement
entitlement issue dated 3 December 2019)
must comply with the
applicable timetable
in Appendix 7A.
Cross reference: item
33 of Appendix 3B.
Number +Class
8 Number and +class Current shares on Ordinary Shares
of all +securities issue:
quoted on ASX (including 265,587,398
the +securities in
section 2 if applicable) Shares on issue
after
issue and
quotation
of the 52,958,908
Tranche
1 shares:
318,546,306
Shares on issue
after
further issue and
quotation
of the 70,042,323
Tranche
2 shares:
388,588,629
---------------------------------
Number +Class
9 Number and +class
of all +securities 500,000 Unlisted Options
not quoted on ASX exercisable
(including the +securities at $0.912 each,
in section 2 if applicable) expiring
1,440,000 11 May 2020
(Remuneration
Options)
1,168,272 Unlisted Options
exercisable
at $0.94 each,
expiring
301,040 19 May 2020
(Remuneration
Options)
583,000 Unlisted Options
exercisable
at $1.031 each,
expiring
561,800 24 January 2022
(Remuneration
Options)
1,450,000 Unlisted Options
exercisable
at $1.031 each,
expiring
280,000 24 January 2022
(Remuneration
800,000 Options)
100,000 Unlisted Options
exercisable
25,000 at $1.108 each,
expiring
15,000 13 March 2022
(Remuneration
65,000 Options)
1,000,000 Unlisted Options
exercisable
at $1.119 each,
expiring
28 March 2022
(Remuneration
Options)
Unlisted Options
exercisable
at $1.114 each,
expiring
30 May 2022
(Remuneration
Options)
Performance Rights
- Class 1
Performance Rights
- Class 4
Performance Rights
- Class 5
Performance Rights
- Class 6
Performance Rights
- Class 7
Performance Rights
- Class 8
Performance Rights
- Class 9
-----------------------------------
10 Dividend policy (in N/A
the case of a trust,
distribution policy)
on the increased capital
(interests)
Part 2 -- Pro rata issue
11 Is security holder approval N/A
required?
12 Is the issue renounceable N/A
or non-renounceable?
13 Ratio in which the +securities N/A
will be offered
14 +Class of +securities N/A
to which the offer relates
15 +Record date to determine N/A
entitlements
16 Will holdings on different N/A
registers (or subregisters)
be aggregated for calculating
entitlements?
17 Policy for deciding entitlements N/A
in relation to fractions
18 Names of countries in N/A
which the entity has security
holders who will not be
sent new offer documents
Note: Security holders
must be told how their
entitlements are to be
dealt with.
Cross reference: rule
7.7.
19 Closing date for receipt N/A
of acceptances or renunciations
20 Names of any underwriters N/A
21 Amount of any underwriting N/A
fee or commission
22 Names of any brokers to N/A
the issue
23 Fee or commission payable N/A
to the broker to the issue
24 Amount of any handling N/A
fee payable to brokers
who lodge acceptances
or renunciations on behalf
of security holders
25 If the issue is contingent N/A
on security holders' approval,
the date of the meeting
26 Date entitlement and acceptance N/A
form and offer documents
will be sent to persons
entitled
27 If the entity has issued N/A
options, and the terms
entitle option holders
to participate on exercise,
the date on which notices
will be sent to option
holders
28 Date rights trading will N/A
begin (if applicable)
-----------------
29 Date rights trading will N/A
end (if applicable)
30 How do security holders N/A
sell their entitlements
in full through a broker?
31 How do security holders N/A
sell part of their entitlements
through a broker and
accept for the balance?
32 How do security holders N/A
dispose of their entitlements
(except by sale through
a broker)?
33 +Issue date N/A
Part 3 -- Quotation of securities
You need only complete this section if you are applying for quotation of securities
34 Type of +securities
(tick one)
(a) X +Securities described in Part 1
(b) All other +securities
Example: restricted securities at the end of the
escrowed period, partly paid securities that become
fully paid, employee incentive share securities
when restriction ends, securities issued on expiry
or conversion of convertible securities
Entities that have ticked box 34(a)
Additional securities forming a new class of securities
Tick to indicate you are providing
the information or documents
35 If the +securities are +equity securities, the
names of the 20 largest holders of the additional
+securities, and the number and percentage of
additional +securities held by those holders
36 If the +securities are +equity securities, a distribution
schedule of the additional +securities setting
out the number of holders in the categories
1 - 1,000
1,001 - 5,000
5,001 - 10,000
10,001 - 100,000
100,001 and over
37 A copy of any trust deed for the additional +securities
Entities that have ticked box 34(b)
38 Number of +securities N/A
for which +quotation
is sought
39 +Class of +securities N/A
for which quotation
is sought
40 Do the +securities N/A
rank equally in all
respects from the +issue
date with an existing
+class of quoted +securities?
If the additional +securities
do not rank equally,
please state:
* the date from which they do
* the extent to which they participate for the next
dividend, (in the case of a trust, distribution) or
interest payment
* the extent to which they do not rank equally, other
than in relation to the next dividend, distribution
or interest payment
41 Reason for request N/A
for quotation now
Example: In the case
of restricted securities,
end of restriction
period
(if issued upon conversion
of another +security,
clearly identify that
other +security)
Number +Class
42 Number and +class of N/A N/A
all +securities quoted
on ASX (including the
+securities in clause
38)
---------
Quotation agreement
1 +Quotation of our additional +securities are in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.
2 We warrant the following to ASX.
-- The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
-- There is no reason why those +securities should not be granted +quotation.
-- An offer of the (+) securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.
Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty
-- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
-- If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.
3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
4 We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.
3 December 2019
Sign here: ............................................................ Date: .........................
(Director/Company secretary)
Catherine Grant-Edwards
Print name: .........................................................
== == == == ==
Appendix 3B - Annexure 1
Calculation of placement capacity under rule 7.1 and rule 7.1A for (+) eligible entities
Introduced 01/08/12
Part 1
Rule 7.1 - Issues exceeding 15% of capital
Step 1: Calculate "A", the base figure from which the placement
capacity is calculated
Insert number of fully paid
ordinary securities on issue
12 months before date of
issue or agreement to issue 264,413,827
-------------------------------------------------------------------------
Add the following: 356,049 fully paid ordinary shares issued
* Number of fully paid ordinary securities issued in 24 July 2018 (ratified by shareholders
that 12 month period under an exception in rule 7.2 27 May 2019)
8,571 fully paid ordinary shares issued
20 December 2018 (ratified by shareholders
* Number of fully paid ordinary securities issued in 27 May 2019)
that 12 month period with shareholder approval 900,000 (fully paid ordinary shares
issued 9 August 2019 on exercise of
options)
* Number of partly paid ordinary securities that became 250,000 (fully paid ordinary shares
fully paid in that 12 month period issued 8 October 2019 on exercise of
options)
15,000 (fully paid ordinary shares issued
Note: 8 October 2019 on vesting of performance
* Include only ordinary securities here - other classes rights)
of equity securities cannot be added
* Include here (if applicable) the securities the
subject of the Appendix 3B to which this form is
annexed
* It may be useful to set out issues of securities on
different dates as separate line items
-------------------------------------------------------------------------
Subtract the number of fully N/A
paid ordinary securities
cancelled during that 12
month period
-------------------------------------------------------------------------
"A" 265,943,447
-------------------------------------------------------------------------
Step 2: Calculate 15% of "A"
"B" 0.15
[Note: this value cannot be
changed]
------------------------------------------------------------------
Multiply "A" by 0.15 39,891,517
------------------------------------------------------------------
Step 3: Calculate "C", the amount of placement capacity under
rule 7.1 that has already been used
Insert number of equity securities 1,168,272 unlisted options
issued or agreed to be issued (27 February 2019) (being 1,724,015
in that 12 month period not unlisted options initially
counting those issued: issued, less 455,800 unlisted
* Under an exception in rule 7.2 options cancelled 7 June 2019,
less 99,943 unlisted options
cancelled 11 October 2019)
* Under rule 7.1A 583,000 unlisted options (26
March 2019)
561,800 unlisted options (18
* With security holder approval under rule 7.1 or rule April 2019)
7.4 1,000,000 performance rights
(14 June 2019) (Class 9)
1,450,000 unlisted options
Note: (14 June 2019)
* This applies to equity securities, unless 26,364,563 fully paid ordinary
specifically excluded - not just ordinary securities shares (agreed to be issued
pursuant to the Placement announced
3 December 2019) (the subject
* Include here (if applicable ) the securities the of this Appendix 3B)
subject of the Appendix 3B to which this form is
annexed
* It may be useful to set out issues of securities on
different dates as separate line items
------------------------------------------------------------------
"C" 31,127,635
------------------------------------------------------------------
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining
placement capacity under rule 7.1
"A" x 0.15
Note: number must be same as
shown in Step 2 39,891,517
------------------------------------------------------------------
Subtract "C"
Note: number must be same as
shown in Step 3 31,127,635
------------------------------------------------------------------
Total ["A" x 0.15] - "C" 8,763,882
------------------------------------------------------------------
Part 2
Rule 7.1A - Additional placement capacity for eligible entities
Step 1: Calculate "A", the base figure from which the placement
capacity is calculated
"A"
Note: number must be same as shown
in Step 1 of Part 1 265,943,447
---------------------------------------
Step 2: Calculate 10% of "A"
"D" 0.10
Note: this value cannot be changed
---------------------------------------
Multiply "A" by 0.10 26,594,345
---------------------------------------
Step 3: Calculate "E", the amount of placement capacity under
rule 7.1A that has already been used
Insert number of equity securities 26,594,345 fully paid ordinary
issued or agreed to be issued in shares (agreed to be issued pursuant
that 12 month period under rule to the Placement announced 3
7.1A December 2019) (the subject of
Notes: this Appendix 3B)
-- This applies to equity securities
- not just ordinary securities
-- Include here - if applicable
- the securities the subject of
the Appendix 3B to which this form
is annexed
-- Do not include equity securities
issued under rule 7.1 (they must
be dealt with in Part 1), or for
which specific security holder
approval has been obtained
-- It may be useful to set out
issues of securities on different
dates as separate line items
---------------------------------------
"E" 26,594,345
---------------------------------------
Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement
capacity under rule 7.1A
"A" x 0.10
Note: number must be same as shown
in Step 2 26,594,345
---------------------------------------
Subtract "E"
Note: number must be same as shown
in Step 3 26,594,345
---------------------------------------
Total ["A" x 0.10] - "E" Nil
---------------------------------------
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
MSCKMMGZVFFGLZG
(END) Dow Jones Newswires
December 03, 2019 02:05 ET (07:05 GMT)
1 Year Danakali Chart |
1 Month Danakali Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
